ROTTERDAM, THE NETHERLANDS, May 12th, 2020 - Quantib, market leader in artificial intelligence solutions for radiology, released an upgrade of their radiology software for dementia and MS brain scan analysis, Quantib® ND Plus. The software is CE marked and cleared for clinical use by the FDA. A substantial amount of new usability features was added, enhancing the clinical relevance and user friendliness of the product beyond previous scope.

 “This is the best product Quantib has released so far”, says Arthur Post Uiterweer, CEO of Quantib. “We have been working in close collaboration with our current customers to get their feedback and ensure this newly released version of our software fits their needs even better. Developing a radiology software product and getting it cleared for clinical use is one thing, constantly improving its usability to make sure our customers genuinely enjoy using the product, is an important next step in further scaling up our business. I am extremely proud of our team for accomplishing this significant release.”

The new update includes customized reports relevant to the organizational requirements, an expansion of the follow up modus offering a longitudinal comparison of all brain structures, and a significant reduction in processing and loading times. With these improvements Quantib is making the product even more user-friendly and the best choice for practices in brain quantification.

About Quantib® ND Plus

Quantib® ND Plus provides the user with accurate quantification of brain atrophy and white matter hyperintensities (WMHs) both related to diseases such as dementia and MS. The software includes automated segmentation of brain structures, reference centile curves per brain structure to enable comparison of the patient’s brain volume to that of representative cross-section of the population, and semi-automatic detection of WMHs. All features are available in a follow-up mode to track atrophy and WMH development. Quantib® ND Plus is installed on site, allowing for patient data to remain locally - and avoid uploading scans to a cloud provider. Additionally, full availability of the software to the user at all times is ensured, implicating continuous processing accessibility without waiting times. 

About Neurodegenerative Disorders

In the upcoming decennia, neurodegenerative diseases will have an enormous impact on society. The WHO claims that currently 50M people are suffering from dementia, a number that increases with 10M each year.1

Although some risks are genetically determined, a 2017 publication in the Lancet shows that 35% of risk factors are modifiable. Therefore, early discovery of dementia or of mild cognitive impairment (often a pre-stage of dementia) is of great importance.

About Quantib

Quantib strives for faster and more accurate diagnosis, supporting adequate and timely patient care. Using state-of-the-art artificial intelligence techniques, Quantib’s software advances the diagnostic pathway by providing solutions related to neurodegeneration, prostate cancer, and breast cancer.

New call-to-action

Bibliography

  1. WMHO - Dementia. (2019). Available at: https://www.who.int/news-room/fact-sheets/detail/dementia. (Accessed: 22nd April 2020)
  2. Livingston, G. et al. Dementia prevention, intervention, and care. Lancet 390, 2673–2734 (2017).